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Introduction and question
Hyperimmunoglobulinemia D and periodic fever syn-
drome (HIDS; MIM# 260920) is a rare autosomal reces-
sive autoinflammatory condition caused by mutations in
the MVK gene, which encodes for mevalonate kinase.
There is no standard treatment for HIDS. Therefore
new therapeutic options might be developed.
Methods and results of this case report
We report on a 2 year-old Austrian boy with recurrent
episodes of fever, febrile seizures, arthralgias, and sple-
nomegaly. Rash and abdominal pain were also seen
occasionally. During attacks an acute-phase response
was detected. Clinical and laboratory improvement was
seen between attacks. These findings led to the tentative
diagnosis of HIDS. Sequencing of the MVK gene
showed a homozygous c.1129G>A (p.Val377Ile, also
known as V377I) mutation in the child, while the
healthy non-consanguineous parents were heterozygous.
The mutation is known to be associated with HIDS.
Therapy with nonsteroidal anti-inflammatory drugs
during attacks had poor benefit. A further febrile epi-
sode resulted in a status epilepticus. Treatment with
canakinumab was initiated and a final dose of 4 mg/kg
every 4 weeks resulted in the disappearance of febrile
attacks and a considerable improvement of patient’s
quality of life during a 6-month follow-up period. The
drug has been well tolerated, and no side effects were
observed.
Conclusion
Treatment with canakinumab is a therapeutical option
for patients with HIDS.
Consent to publish
Written informated consent for publication of their clini-
cal details was obtained from the patient/parent/guardian/
relative of the patient.
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